+42%

est. 2Y upside i

FinTechHealthcareInsurTechSeries D+

Rank

#1102

Sector

Fintech, HealthTech, Insurance

Est. Liquidity

~2Y

Data Quality

Data: High

Oscar Health offers a moderate upside of ~42% over 2 years, with a base case multiple convergence.

Last updated: July 19, 2026

Bull (18%)+100%

Oscar achieves IPO or becomes category leader, expanding multiple to 1.2x on projected $22B revenue, yielding 100% upside (capped).

Base (45%)+76%

Multiple converges to public comp average of ~0.7x on $22B revenue, yielding 76% upside; company remains profitable and independent.

Bear (38%)-25%

Multiple compresses to 0.3x due to aggressive competition from incumbents, medical loss ratio spikes, and slower growth, resulting in ~25% decline.

Est. time to liquidity~2.0 years

Preference Stack Risk

moderate

Funding Intensity

19%

Total preferred overhang of $1.63B represents ~18.6% of current valuation, moderate risk.

Dilution Risk

low

Company is profitable and cash-flow positive, unlikely to raise capital within 2 years.

Secondary Liquidity

moderate

Secondary market trades have occurred, suggesting some liquidity but not active.

View all 16 open roles at Hioscar →

Last updated: July 3, 2026

Questions to Ask at the Interview

Strategic questions based on Hioscar's data — designed to show you've done your homework.

  • 1

    “How would Oscar differentiate from incumbents in an increasingly digital market?”

  • 2

    “What drives Oscar's medical loss ratio and how can it be controlled?”

  • 3

    “Given the secondary market liquidity and preference stack, how do you view the risk-reward of equity compensation here?”

Community

Valuation Sentiment

Our model estimates +42% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.